A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
|Articles|April 12, 2022
Looking to the Future of AD Treatment
Author(s)Colleen Hall
Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.
Advertisement
In this video, taken at the at the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11, in Baltimore, Maryland, Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment, noting that the addition of targeted agents is enabling better responses in patients.
Advertisement
Related to this article
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermatology Times Monthly FDA and Pipeline Review: October 2026
2
Updated HS Guidelines Emphasize Biologics and Early Intervention
3
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
4
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
5